Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Aptinyx Inc.APTX · Entity 120922 | Director | May 26, 2022 | May 31, 2022 |
| Editas Medicine, Inc.EDIT · Entity 5502 | Director · CEO | September 03, 2026 | September 04, 2026 |
| Sarepta Therapeutics, Inc.SRPT · Entity 4426 | EVP, R&D & CMO | February 28, 2021 | March 11, 2021 |
| Unity Biotechnology, Inc.UBX · Entity 77428 | Director | June 21, 2024 | June 21, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Aptinyx Inc.
Report date May 26, 2022 · Filed May 31, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.50 · Expires 2032-05-25 | Direct | 40,000 |
Reported balance
After 2022-05-26 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2022-05-26 · Grant · Acquired 40,000 · Balance 40,000 F1: This options vests in ratable monthly installments over one year from the date of grant. |
Filing footnotes · ownership attribution and instrument terms
F1: This options vests in ratable monthly installments over one year from the date of grant.
Editas Medicine, Inc.
Report date September 03, 2026 · Filed September 04, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 243,189 |
Reported balance
After 2026-09-03 transaction · row 1
1 source rowRow 1 · 2026-09-03 · Sale · Disposed 5,124 · Balance 243,189 F1: Sale was effected pursuant to a durable automatic sales instruction plan adopted by the Reporting Person on April 13, 2022, and represents the sale of shares by the Issuer necessary to meet tax withholding obligations as a result of vesting in restricted stock units on September 2, 2026. The sale does not represent a discretionary trade by the Reporting Person. F2: This transaction was executed in multiple trades at prices ranging from $3.0050 to $3.0372. The price reported above reflects the weighted average purchase price. The Reporting Person hereby undertakes to provide upon request, to the SEC staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. |
Filing footnotes · ownership attribution and instrument terms
F1: Sale was effected pursuant to a durable automatic sales instruction plan adopted by the Reporting Person on April 13, 2022, and represents the sale of shares by the Issuer necessary to meet tax withholding obligations as a result of vesting in restricted stock units on September 2, 2026. The sale does not represent a discretionary trade by the Reporting Person.
F2: This transaction was executed in multiple trades at prices ranging from $3.0050 to $3.0372. The price reported above reflects the weighted average purchase price. The Reporting Person hereby undertakes to provide upon request, to the SEC staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected.
Sarepta Therapeutics, Inc.
Report date February 28, 2021 · Filed March 11, 2021 · Amendment
Amendment: balances below belong to this corrected disclosure, not necessarily a complete replacement of earlier positions.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 28,546 |
Last balance in matching sequence
After 2021-03-03 transaction · row 2
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
2 source rowsRow 1 · 2021-02-28 · Tax withholding · Disposed 524 · Balance 13,546 F1: Shares were withheld by the Company to satisfy tax withholding obligations related to vesting of restricted stock units granted on February 28, 2020. F2: On March 5, 2021, the Form 4 filed for the reporting person overstated the number of shares held by the reporting person. This amended form corrects such error by reporting the number of shares withheld by the Company to satisfy tax withholding obligations related to vesting of restricted stock units on February 28, 2021 and by reporting the corrected total amount of securities directly owned by the reporting person following a grant of restricted stock units on March 3, 2021. Row 2 · 2021-03-03 · Grant · Acquired 15,000 · Balance 28,546 F2: On March 5, 2021, the Form 4 filed for the reporting person overstated the number of shares held by the reporting person. This amended form corrects such error by reporting the number of shares withheld by the Company to satisfy tax withholding obligations related to vesting of restricted stock units on February 28, 2021 and by reporting the corrected total amount of securities directly owned by the reporting person following a grant of restricted stock units on March 3, 2021. |
Filing footnotes · ownership attribution and instrument terms
F1: Shares were withheld by the Company to satisfy tax withholding obligations related to vesting of restricted stock units granted on February 28, 2020.
F2: On March 5, 2021, the Form 4 filed for the reporting person overstated the number of shares held by the reporting person. This amended form corrects such error by reporting the number of shares withheld by the Company to satisfy tax withholding obligations related to vesting of restricted stock units on February 28, 2021 and by reporting the corrected total amount of securities directly owned by the reporting person following a grant of restricted stock units on March 3, 2021.
Unity Biotechnology, Inc.
Report date June 21, 2024 · Filed June 21, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.38 · Expires 2034-06-20 | Direct | 10,000 |
Reported balance
After 2024-06-21 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2024-06-21 · Grant · Acquired 10,000 · Balance 10,000 F1: The underlying shares subject to the option vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of (i) the one-year anniversary measured from June 21, 2024 or (ii) the date of the 2025 Annual Meeting of the Issuer's stockholders, assuming continuous service as a Director until such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The underlying shares subject to the option vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of (i) the one-year anniversary measured from June 21, 2024 or (ii) the date of the 2025 Annual Meeting of the Issuer's stockholders, assuming continuous service as a Director until such vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 03, 2026 Filed Sep 4, 2026 20:22 UTC | Editas Medicine, Inc. EDIT · Entity 5502 | SaleCommon Stock | 5,124 | $3.04 | $15,562.61 |
DisclosureSEC source: 0001742084-26-000003 · wk-form4_1788553359.xml · nonDerivative · entry 1 O'Neill Gilmore Neil · CIK 0001742084 · Director · CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 243,189 F1 · kind: Sale was effected pursuant to a durable automatic sales instruction plan adopted by the Reporting Person on April 13, 2022, and represents the sale of shares by the Issuer necessary to meet tax withholding obligations as a result of vesting in restricted stock units on September 2, 2026. The sale does not represent a discretionary trade by the Reporting Person. F2 · price: This transaction was executed in multiple trades at prices ranging from $3.0050 to $3.0372. The price reported above reflects the weighted average purchase price. The Reporting Person hereby undertakes to provide upon request, to the SEC staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| June 03, 2026 Filed Jun 5, 2026 20:33 UTC | Editas Medicine, Inc. EDIT · Entity 5502 | SaleCommon Stock | 15,380 | $2.70 | $41,542.92 |
DisclosureSEC source: 0001650664-26-000056 · wk-form4_1780691579.xml · nonDerivative · entry 1 O'Neill Gilmore Neil · CIK 0001742084 · Director · CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 248,313 F1 · kind: Sale was effected pursuant to a durable automatic sales instruction plan adopted by the Reporting Person on April 13, 2022, and represents the sale of shares by the Issuer necessary to meet tax withholding obligations as a result of vesting in restricted stock units on June 2, 2026. The sale does not represent a discretionary trade by the Reporting Person. F2 · price: This transaction was executed in multiple trades at prices ranging from $2.7010 to $2.7250. The price reported above reflects the weighted average purchase price. The Reporting Person hereby undertakes to provide upon request, to the SEC staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| March 12, 2026 Filed Mar 16, 2026 20:37 UTC | Editas Medicine, Inc. EDIT · Entity 5502 | GrantStock Option (right to buy) · Derivative | 1,015,200 | $0.00 Strike: $2.54 | $0.00 |
DisclosureSEC source: 0001650664-26-000023 · wk-form4_1773693426.xml · derivative · entry 1 O'Neill Gilmore Neil · CIK 0001742084 · Director · CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,015,200 Underlying: Common Stock · 1,015,200 shares Expires 2036-03-11 F1 · derivative.exercise_date: This option was granted on March 12, 2026 and is scheduled to vest over four years in equal monthly installments beginning on April 12, 2026 through March 12, 2030. Read SEC document |
| March 03, 2026 Filed Mar 4, 2026 21:56 UTC | Editas Medicine, Inc. EDIT · Entity 5502 | SaleCommon Stock | 5,394 | $2.02 | $10,894.26 |
DisclosureSEC source: 0001650664-26-000009 · wk-form4_1772661358.xml · nonDerivative · entry 1 O'Neill Gilmore Neil · CIK 0001742084 · Director · CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 263,693 F1 · kind: Sale was effected pursuant to a durable automatic sales instruction plan adopted by the Reporting Person on April 13, 2022, and represents the sale of shares by the Issuer necessary to meet tax withholding obligations as a result of vesting in restricted stock units on March 2, 2026. The sale does not represent a discretionary trade by the Reporting Person. F2 · price: This transaction was executed in multiple trades at prices ranging from $2.0050 to $2.0204 The price reported above reflects the weighted average purchase price. The Reporting Person hereby undertakes to provide upon request, to the SEC staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| December 03, 2025 Filed Dec 4, 2025 21:38 UTC | Editas Medicine, Inc. EDIT · Entity 5502 | SaleCommon Stock | 5,603 | $2.15 | $12,063.82 |
DisclosureSEC source: 0001650664-25-000162 · wk-form4_1764884318.xml · nonDerivative · entry 1 O'Neill Gilmore Neil · CIK 0001742084 · Director · CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 269,087 F1 · kind: Sale was effected pursuant to a durable automatic sales instruction plan adopted by the Reporting Person on April 13, 2022, and represents the sale of shares by the Issuer necessary to meet tax withholding obligations as a result of vesting in restricted stock units on December 2, 2025. The sale does not represent a discretionary trade by the Reporting Person. Read SEC document |
| September 03, 2025 Filed Sep 4, 2025 20:20 UTC | Editas Medicine, Inc. EDIT · Entity 5502 | SaleCommon Stock | 5,592 | $2.60 | $14,517.39 |
DisclosureSEC source: 0001650664-25-000141 · wk-form4_1757017197.xml · nonDerivative · entry 1 O'Neill Gilmore Neil · CIK 0001742084 · Director · CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 274,690 F1 · kind: Sale was effected pursuant to a durable automatic sales instruction plan adopted by the Reporting Person on April 13, 2022, and represents the sale of shares by the Issuer necessary to meet tax withholding obligations as a result of vesting in restricted stock units on September 2, 2025. The sale does not represent a discretionary trade by the Reporting Person. Read SEC document |
| June 03, 2025 Filed Jun 4, 2025 22:36 UTC | Editas Medicine, Inc. EDIT · Entity 5502 | SaleCommon Stock | 15,192 | $1.72 | $26,195.57 |
DisclosureSEC source: 0001650664-25-000089 · wk-form4_1749076593.xml · nonDerivative · entry 1 O'Neill Gilmore Neil · CIK 0001742084 · Director · CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 280,282 F1 · kind: Sale was effected pursuant to a durable automatic sales instruction plan adopted by the Reporting Person on April 13, 2022, and represents the sale of shares by the Issuer necessary to meet tax withholding obligations as a result of vesting in restricted stock units on June 2, 2025. The sale does not represent a discretionary trade by the Reporting Person. F2 · price: This transaction was executed in multiple trades at prices ranging from $1.7239 to $1.7566 . The price reported above reflects the weighted average purchase price. The Reporting Person hereby undertakes to provide upon request, to the SEC staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| March 08, 2025 Filed Mar 27, 2025 20:37 UTC | Editas Medicine, Inc. EDIT · Entity 5502 | GrantStock Option (right to buy) · Derivative | 175,000 | $0.00 Strike: $1.72 | $0.00 |
DisclosureSEC source: 0001650664-25-000037 · wk-form4_1743107853.xml · derivative · entry 2 O'Neill Gilmore Neil · CIK 0001742084 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 175,000 Underlying: Common Stock · 175,000 shares Expires 2035-03-07 F2 · derivative.exercise_date: This option was granted on March 8, 2025 and is scheduled to vest in full on September 8, 2026. Read SEC document |
| March 08, 2025 Filed Mar 27, 2025 20:37 UTC | Editas Medicine, Inc. EDIT · Entity 5502 | GrantStock Option (right to buy) · Derivative | 828,000 | $0.00 Strike: $1.72 | $0.00 |
DisclosureSEC source: 0001650664-25-000037 · wk-form4_1743107853.xml · derivative · entry 1 O'Neill Gilmore Neil · CIK 0001742084 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 828,000 Underlying: Common Stock · 828,000 shares Expires 2035-03-07 F1 · derivative.exercise_date: This option was granted on March 8, 2025 and is scheduled to vest over four years in equal monthly installments beginning on April 8, 2025 through March 8, 2029. Read SEC document |
| March 04, 2025 Filed Mar 5, 2025 21:43 UTC | Editas Medicine, Inc. EDIT · Entity 5502 | SaleCommon Stock | 16,632 | $1.71 | $28,452.36 |
DisclosureSEC source: 0001650664-25-000026 · wk-form4_1741210979.xml · nonDerivative · entry 1 O'Neill Gilmore Neil · CIK 0001742084 · Director · CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 295,474 F1 · kind: Sale was effected pursuant to a durable automatic sales instruction plan adopted by the Reporting Person on April 13, 2022, and represents the sale of shares by the Issuer necessary to meet tax withholding obligations as a result of vesting in restricted stock units on March 3, 2025. The sale does not represent a discretionary trade by the Reporting Person. F2 · price: This transaction was executed in multiple trades at prices ranging from $1.7107 to $1.7125 . The price reported above reflects the weighted average purchase price. The Reporting Person hereby undertakes to provide upon request, to the SEC staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| December 03, 2024 Filed Dec 5, 2024 21:40 UTC | Editas Medicine, Inc. EDIT · Entity 5502 | SaleCommon Stock | 1,618 | $2.08 | $3,361.23 |
DisclosureSEC source: 0001650664-24-000126 · wk-form4_1733434825.xml · nonDerivative · entry 1 O'Neill Gilmore Neil · CIK 0001742084 · Director · CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 312,106 F1 · kind: Sale was effected pursuant to a durable automatic sales instruction plan adopted by the Reporting Person on April 13, 2022, and represents the sale of shares by the Issuer necessary to meet tax withholding obligations as a result of vesting in restricted stock units on December 2, 2024. The sale does not represent a discretionary trade by the Reporting Person. F2 · price: This transaction was executed in multiple trades at prices ranging from $2.0550 to $2.0783. The price reported above reflects the weighted average purchase price. The Reporting Person hereby undertakes to provide upon request, to the SEC staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| September 04, 2024 Filed Sep 6, 2024 20:18 UTC | Editas Medicine, Inc. EDIT · Entity 5502 | SaleCommon Stock | 1,555 | $3.42 | $5,325.41 |
DisclosureSEC source: 0001650664-24-000103 · wk-form4_1725653893.xml · nonDerivative · entry 1 O'Neill Gilmore Neil · CIK 0001742084 · Director · CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 313,724 F1 · kind: Sale was effected pursuant to a durable automatic sales instruction plan adopted by the Reporting Person on April 13, 2022, and represents the sale of shares by the Issuer necessary to meet tax withholding obligations as a result of vesting in restricted stock units on September 2, 2024. The sale does not represent a discretionary trade by the Reporting Person. F2 · price: This transaction was executed in multiple trades at prices ranging from $3.4246 to $3.4503. The price reported above reflects the weighted average purchase price. The Reporting Person hereby undertakes to provide upon request, to the SEC staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| June 21, 2024 Filed Jun 21, 2024 16:30 UTC | Unity Biotechnology, Inc. UBX · Entity 77428 | GrantStock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $1.38 | $0.00 |
DisclosureSEC source: 0000950170-24-076285 · ownership.xml · derivative · entry 1 O'Neill Gilmore Neil · CIK 0001742084 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2034-06-20 F1 · derivative.exercise_date: The underlying shares subject to the option vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of (i) the one-year anniversary measured from June 21, 2024 or (ii) the date of the 2025 Annual Meeting of the Issuer's stockholders, assuming continuous service as a Director until such vesting date. Read SEC document |
| June 04, 2024 Filed Jun 6, 2024 20:17 UTC | Editas Medicine, Inc. EDIT · Entity 5502 | SaleCommon Stock | 12,191 | $5.50 | $66,996.86 |
DisclosureSEC source: 0001650664-24-000076 · wk-form4_1717705020.xml · nonDerivative · entry 1 O'Neill Gilmore Neil · CIK 0001742084 · Director · CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 315,279 F1 · kind: Sale was effected pursuant to a durable automatic sales instruction plan adopted by the Reporting Person on April 13, 2022, and represents the sale of shares by the Issuer necessary to meet tax withholding obligations as a result of vesting in restricted stock units on June 2, 2024. The sale does not represent a discretionary trade by the Reporting Person. Read SEC document |
| March 05, 2024 Filed Mar 6, 2024 01:00 UTC | Editas Medicine, Inc. EDIT · Entity 5502 | SaleCommon Stock | 77,824 | $9.42 | $732,884.17 |
DisclosureSEC source: 0001650664-24-000015 · wk-form4_1709686792.xml · nonDerivative · entry 4 O'Neill Gilmore Neil · CIK 0001742084 · Director · CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 327,470 F4 · kind: Sale was effected pursuant to a durable automatic sales instruction plan adopted by the Reporting Person on April 13, 2022, and represents the sale of shares by the Issuer necessary to meet tax withholding obligations as a result of vesting in restricted stock units on March 2, 2024. The sale does not represent a discretionary trade by the Reporting Person. F5 · price: This transaction was executed in multiple trades at prices ranging from $9.1036 to $9.4298. The price reported above reflects the weighted average purchase price. The Reporting Person hereby undertakes to provide upon request, to the SEC staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| March 02, 2024 Filed Mar 6, 2024 01:00 UTC | Editas Medicine, Inc. EDIT · Entity 5502 | GrantStock Option (right to buy) · Derivative | 392,100 | $0.00 Strike: $10.53 | $0.00 |
DisclosureSEC source: 0001650664-24-000015 · wk-form4_1709686792.xml · derivative · entry 5 O'Neill Gilmore Neil · CIK 0001742084 · Director · CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 392,100 Underlying: Common Stock · 392,100 shares Expires 2034-03-01 F6 · derivative.exercise_date: This option was granted on March 2, 2024 and is scheduled to vest over four years in equal monthly installments beginning on April 2, 2024 through March 2, 2028. Read SEC document |
| March 02, 2024 Filed Mar 6, 2024 01:00 UTC | Editas Medicine, Inc. EDIT · Entity 5502 | GrantCommon Stock | 72,212 | $0.00 | $0.00 |
DisclosureSEC source: 0001650664-24-000015 · wk-form4_1709686792.xml · nonDerivative · entry 3 O'Neill Gilmore Neil · CIK 0001742084 · Director · CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 405,294 F3 · kind: Reflects the vesting, upon the achievement of a business development milestone, of a portion of a performance-based restricted stock unit award originally granted on June 2, 2022. Read SEC document |
| March 02, 2024 Filed Mar 6, 2024 01:00 UTC | Editas Medicine, Inc. EDIT · Entity 5502 | GrantCommon Stock | 72,213 | $0.00 | $0.00 |
DisclosureSEC source: 0001650664-24-000015 · wk-form4_1709686792.xml · nonDerivative · entry 2 O'Neill Gilmore Neil · CIK 0001742084 · Director · CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 333,082 F2 · kind: Reflects the vesting, upon the achievement of a specified research and development milestone, of a portion of a performance-based restricted stock unit award originally granted on June 2, 2022. Read SEC document |
| March 02, 2024 Filed Mar 6, 2024 01:00 UTC | Editas Medicine, Inc. EDIT · Entity 5502 | GrantCommon Stock | 130,700 | $0.00 | $0.00 |
DisclosureSEC source: 0001650664-24-000015 · wk-form4_1709686792.xml · nonDerivative · entry 1 O'Neill Gilmore Neil · CIK 0001742084 · Director · CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 260,869 F1 · kind: The common stock received by the Reporting Person was in connection with the grant of a restricted stock unit award to the Reporting Person, for no consideration, and which is scheduled to vest over four years with 25% of the units vesting on March 2, 2025 and the remaining 75% of the units scheduled to vest in equal quarterly installments thereafter through March 2, 2028. Read SEC document |
| June 23, 2023 Filed Jun 26, 2023 17:12 UTC | Unity Biotechnology, Inc. UBX · Entity 77428 | GrantStock Option (Right to Buy) · Derivative | 6,000 | $0.00 Strike: $3.25 | $0.00 |
DisclosureSEC source: 0000899243-23-016504 · doc4.xml · derivative · entry 1 O'Neill Gilmore Neil · CIK 0001742084 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,000 Underlying: Common Stock · 6,000 shares Expires 2033-06-22 F1 · derivative.exercise_date: The underlying shares subject to the option vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of (i) the one-year anniversary measured from June 23, 2023 or (ii) the date of the 2024 Annual Meeting of the Issuer's stockholders, assuming continuous service as a Director until such vesting date. Read SEC document |
| June 05, 2023 Filed Jun 7, 2023 20:30 UTC | Editas Medicine, Inc. EDIT · Entity 5502 | SaleCommon Stock | 6,486 | $9.50 | $61,637.76 |
DisclosureSEC source: 0001415889-23-009369 · form4-06072023_040605.xml · nonDerivative · entry 1 O'Neill Gilmore Neil · CIK 0001742084 · Director · CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 130,169 F1 · kind: Sale was effected pursuant to a durable automatic sales instruction plan adopted by the Reporting Person on April 13, 2022, and represents the sale of shares by the Issuer necessary to meet tax withholding obligations as a result of vesting in restricted stock units on June 2, 2023. The sale does not represent a discretionary trade by the Reporting Person. F2 · price: This transaction was executed in multiple trades at prices ranging from $9.4600 to $9.5034. The price reported above reflects the weighted average purchase price. The Reporting Person hereby undertakes to provide upon request, to the SEC staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| March 02, 2023 Filed Mar 6, 2023 21:30 UTC | Editas Medicine, Inc. EDIT · Entity 5502 | GrantStock Option (right to buy) · Derivative | 150,000 | $0.00 Strike: $8.72 | $0.00 |
DisclosureSEC source: 0001415889-23-004313 · form4-03062023_040304.xml · derivative · entry 2 O'Neill Gilmore Neil · CIK 0001742084 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 150,000 Underlying: Common Stock · 150,000 shares Expires 2033-03-01 F2 · derivative.exercise_date: This option was granted on March 2, 2023 and is scheduled to vest over four years in equal monthly installments beginning on April 2, 2023 through March 2, 2027. Read SEC document |
| March 02, 2023 Filed Mar 6, 2023 21:30 UTC | Editas Medicine, Inc. EDIT · Entity 5502 | GrantCommon Stock | 50,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-23-004313 · form4-03062023_040304.xml · nonDerivative · entry 1 O'Neill Gilmore Neil · CIK 0001742084 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 136,655 F1 · security: The common stock received by the Reporting Person was in connection with the grant of a restricted stock unit award to the Reporting Person, for no consideration, and which is scheduled to vest over four years with 25% of the units vesting on March 2, 2024 and the remaining 75% of the units scheduled to vest in equal quarterly installments thereafter through March 2, 2027. Read SEC document |
| June 24, 2022 Filed Jun 27, 2022 18:10 UTC | Unity Biotechnology, Inc. UBX · Entity 77428 | GrantStock Option (Right to Buy) · Derivative | 25,000 | $0.00 Strike: $0.59 | $0.00 |
DisclosureSEC source: 0000899243-22-024228 · doc4.xml · derivative · entry 1 O'Neill Gilmore Neil · CIK 0001742084 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2032-06-23 F1 · derivative.exercise_date: The underlying shares subject to the option vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of (i) the one-year anniversary measured from June 24, 2022 or (ii) the date of the 2023 Annual Meeting of the Issuer's stockholders, assuming continuous service as a Director until such vesting date. Read SEC document |
| June 02, 2022 Filed Jun 6, 2022 20:44 UTC | Editas Medicine, Inc. EDIT · Entity 5502 | GrantStock Option (right to buy) · Derivative | 950,209 | $0.00 Strike: $11.54 | $0.00 |
DisclosureSEC source: 0001415889-22-006159 · form4-06062022_010612.xml · derivative · entry 2 O'Neill Gilmore Neil · CIK 0001742084 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 950,209 Underlying: Common Stock · 950,209 shares Expires 2032-06-01 F2 · derivative.exercise_date: This option was granted on June 2, 2022 and is scheduled to vest over four years, with 25% of the shares scheduled to vest on June 2, 2023 and the remaining 75% of the shares scheduled to vest in equal monthly installments thereafter through June 2, 2026. Read SEC document |
| June 02, 2022 Filed Jun 6, 2022 20:44 UTC | Editas Medicine, Inc. EDIT · Entity 5502 | GrantCommon Stock | 86,655 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-22-006159 · form4-06062022_010612.xml · nonDerivative · entry 1 O'Neill Gilmore Neil · CIK 0001742084 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 86,655 F1 · security: The common stock received by the Reporting Person was in connection with the grant of a restricted stock unit award to the Reporting Person, for no consideration, and which is scheduled to vest over four years in equal yearly installments of one-fourth of the shares, with the first such installment to vest on June 2, 2023 continuing through June 2, 2026. Read SEC document |
| May 26, 2022 Filed May 31, 2022 16:32 UTC | Aptinyx Inc. APTX · Entity 120922 | GrantStock Option (Right to Buy) · Derivative | 40,000 | $0.00 Strike: $0.50 | $0.00 |
DisclosureSEC source: 0001415889-22-005911 · form4-05312022_040536.xml · derivative · entry 1 O'Neill Gilmore Neil · CIK 0001742084 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2032-05-25 F1 · derivative.exercise_date: This options vests in ratable monthly installments over one year from the date of grant. Read SEC document |
| October 19, 2021 Filed Oct 22, 2021 16:19 UTC | Aptinyx Inc. APTX · Entity 120922 | GrantStock Option (Right to Buy) · Derivative | 80,000 | $0.00 Strike: $2.26 | $0.00 |
DisclosureSEC source: 0001415889-21-004946 · form4-10222021_011005.xml · derivative · entry 1 O'Neill Gilmore Neil · CIK 0001742084 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,000 Underlying: Common Stock · 80,000 shares Expires 2031-10-18 F1 · derivative.exercise_date: This option vests over a three-year period with one-third of the option vesting on the first anniversary of the date of grant and the remaining two-thirds vesting in ratable monthly installments thereafter Read SEC document |
| June 24, 2021 Filed Jun 28, 2021 17:26 UTC | Unity Biotechnology, Inc. UBX · Entity 77428 | GrantStock Option (Right to Buy) · Derivative | 13,425 | $0.00 Strike: $4.18 | $0.00 |
DisclosureSEC source: 0000899243-21-026244 · doc4.xml · derivative · entry 1 O'Neill Gilmore Neil · CIK 0001742084 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,425 Underlying: Common Stock · 13,425 shares Expires 2031-06-23 F1 · derivative.exercise_date: The underlying shares subject to the option vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of (i) the one-year anniversary measured from June 24, 2021 or (ii) the date of the 2022 Annual Meeting of the Issuer's stockholders, assuming continuous service as a Director until such vesting date. Read SEC document |
| March 03, 2021 Filed Mar 6, 2021 01:05 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | GrantStock Option (right to buy) · Derivative | 60,000 | $0.00 Strike: $87.11 | $0.00 |
DisclosureSEC source: 0001209191-21-018420 · doc4.xml · derivative · entry 2 O'Neill Gilmore Neil · CIK 0001742084 · EVP, R&D & CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,000 Underlying: Common Stock · 60,000 shares Expires 2031-03-03 F2 · derivative.exercise_date: Represents the date upon which the first 25% of the option granted vests. 1/48th of the total granted option vests and become exercisable on each monthly anniversary thereafter. Read SEC document |
| March 03, 2021 Filed Mar 6, 2021 01:05 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | GrantCommon Stock | 15,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-018420 · doc4.xml · nonDerivative · entry 1 O'Neill Gilmore Neil · CIK 0001742084 · EVP, R&D & CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,070 F1 · price: The Reporting Person was granted restricted stock units ("RSUs"). Each RSU represents the right to receive one share of common stock. 25% of the shares of common stock underlying each RSU will vest and become exercisable on the first anniversary of the grant date, and additional 25% will vest and become exercisable on each anniversary of the Grant Date thereafter, such that the RSUs will be fully vested and exercisable on the fourth anniversary of the grant date. Read SEC document |
| March 03, 2021 Filed Mar 11, 2021 01:02 UTC Amendment | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | GrantCommon Stock | 15,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-019668 · doc4a.xml · nonDerivative · entry 2 O'Neill Gilmore Neil · CIK 0001742084 · EVP, R&D & CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,546 F2 · balance_after: On March 5, 2021, the Form 4 filed for the reporting person overstated the number of shares held by the reporting person. This amended form corrects such error by reporting the number of shares withheld by the Company to satisfy tax withholding obligations related to vesting of restricted stock units on February 28, 2021 and by reporting the corrected total amount of securities directly owned by the reporting person following a grant of restricted stock units on March 3, 2021. Read SEC document |
| February 28, 2021 Filed Mar 11, 2021 01:02 UTC Amendment | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | Tax withholdingCommon Stock | 524 | $86.97 | $45,572.28 |
DisclosureSEC source: 0001209191-21-019668 · doc4a.xml · nonDerivative · entry 1 O'Neill Gilmore Neil · CIK 0001742084 · EVP, R&D & CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,546 F1 · kind: Shares were withheld by the Company to satisfy tax withholding obligations related to vesting of restricted stock units granted on February 28, 2020. F2 · balance_after: On March 5, 2021, the Form 4 filed for the reporting person overstated the number of shares held by the reporting person. This amended form corrects such error by reporting the number of shares withheld by the Company to satisfy tax withholding obligations related to vesting of restricted stock units on February 28, 2021 and by reporting the corrected total amount of securities directly owned by the reporting person following a grant of restricted stock units on March 3, 2021. Read SEC document |
| December 10, 2020 Filed Dec 14, 2020 17:16 UTC | Unity Biotechnology, Inc. UBX · Entity 77428 | GrantStock Option (Right to Buy) · Derivative | 50,000 | $0.00 Strike: $6.12 | $0.00 |
DisclosureSEC source: 0000899243-20-033757 · doc4.xml · derivative · entry 1 O'Neill Gilmore Neil · CIK 0001742084 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2030-12-09 F1 · derivative.exercise_date: Shares subject to the stock option vest and become exercisable in successive, equal monthly installments over a 36-month period commencing on December 10, 2020 (the "Vesting Commencement Date"), so that 100% of the shares become fully vested and exercisable on the third anniversary of the Vesting Commencement Date, subject to Reporting Person's continued service relationship with the Issuer on each such vesting date. Read SEC document |
| February 28, 2020 Filed Feb 29, 2020 01:02 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | GrantStock option (right to buy) · Derivative | 37,500 | $0.00 Strike: $114.47 | $0.00 |
DisclosureSEC source: 0001209191-20-014228 · doc4.xml · derivative · entry 2 O'Neill Gilmore Neil · CIK 0001742084 · EVP, R&D & CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,500 Underlying: Common Stock · 37,500 shares Expires 2030-02-28 F2 · derivative.exercise_date: 25% of the option granted vests and is exercisable on the first anniversary of the date of grant and 1/48th of the total granted option will vest and become exercisable on each monthly anniversary thereafter, such that the option will be fully vested and exercisable on the fourth anniversary of the date of grant. Read SEC document |
| February 28, 2020 Filed Feb 29, 2020 01:02 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | GrantCommon Stock | 6,700 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-014228 · doc4.xml · nonDerivative · entry 1 O'Neill Gilmore Neil · CIK 0001742084 · EVP, R&D & CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,070 F1 · shares: The Reporting Person was granted restricted stock units ("RSUs"). Each RSU represents the right to receive one share of common stock. 25% of the shares of common stock underlying each RSU will vest and become exercisable on the first anniversary of the grant date, and additional 25% will vest and become exercisable on each anniversary of the Grant Date thereafter, such that the RSUs will be fully vested and exercisable on the fourth anniversary of the grant date. F1 · price: The Reporting Person was granted restricted stock units ("RSUs"). Each RSU represents the right to receive one share of common stock. 25% of the shares of common stock underlying each RSU will vest and become exercisable on the first anniversary of the grant date, and additional 25% will vest and become exercisable on each anniversary of the Grant Date thereafter, such that the RSUs will be fully vested and exercisable on the fourth anniversary of the grant date. Read SEC document |
| May 24, 2019 Filed May 25, 2019 00:07 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | Tax withholdingCommon Stock | 4,630 | $119.31 | $552,405.30 |
DisclosureSEC source: 0001209191-19-032835 · doc4.xml · nonDerivative · entry 2 O'Neill Gilmore Neil · CIK 0001742084 · EVP, R&D & CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,370 F2 · price: Shares were sold by Sarepta Therapeutics, Inc. to satisfy tax obligations related to the vesting of restricted stock units. Read SEC document |
| May 23, 2019 Filed May 25, 2019 00:07 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | Exercise / conversionRestricted Stock Units · Derivative | 12,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-032835 · doc4.xml · derivative · entry 3 O'Neill Gilmore Neil · CIK 0001742084 · EVP, R&D & CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 12,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Sarepta Therapeutics, Inc. common stock. F3 · derivative.expiration_date: The restricted stock units have vested on May 23, 2019. Read SEC document |
| May 23, 2019 Filed May 25, 2019 00:07 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | Exercise / conversionCommon Stock | 12,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-19-032835 · doc4.xml · nonDerivative · entry 1 O'Neill Gilmore Neil · CIK 0001742084 · EVP, R&D & CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of Sarepta Therapeutics, Inc. common stock. Read SEC document |
| March 04, 2019 Filed Mar 5, 2019 01:09 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | GrantStock option (right to buy) · Derivative | 55,000 | $0.00 Strike: $145.48 | $0.00 |
DisclosureSEC source: 0001209191-19-016044 · doc4.xml · derivative · entry 1 O'Neill Gilmore Neil · CIK 0001742084 · EVP, R&D & CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,000 Underlying: Common Stock · 55,000 shares Expires 2029-03-04 F1 · derivative.exercise_date: 25% of the option granted vests and is exercisable on the first anniversary of the date of grant and 1/48th of the total granted option will vest and become exercisable on each monthly anniversary thereafter, such that the option will be fully vested and exercisable on the fourth anniversary of the date of grant. Read SEC document |
| June 07, 2018 Filed Jun 11, 2018 22:11 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | GrantRestricted Stock Units · Derivative | 12,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-037075 · doc4.xml · derivative · entry 2 O'Neill Gilmore Neil · CIK 0001742084 · SVP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,000 Underlying: Common Stock · 12,000 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Sarepta Therapeutics, Inc. common stock. F3 · derivative.expiration_date: The restricted stock units will vest on May 23, 2019. Read SEC document |
| June 07, 2018 Filed Jun 11, 2018 22:11 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | GrantStock option (right to buy) · Derivative | 100,000 | $0.00 Strike: $96.23 | $0.00 |
DisclosureSEC source: 0001209191-18-037075 · doc4.xml · derivative · entry 1 O'Neill Gilmore Neil · CIK 0001742084 · SVP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2028-06-07 F1 · derivative.exercise_date: 25% of the option granted vests and is exercisable on the first anniversary of the date of grant and 1/48th of the total granted option will vest and become exercisable on each monthly anniversary thereafter, such that the option will be fully vested and exercisable on the fourth anniversary of the date of grant. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.